Holen Sie sich die Stockscreener-App
148.75
1.77%
2.58
Schlusskurs vom Vortag:
$146.17
Offen:
$147.24
24-Stunden-Volumen:
2.10M
Relative Volume:
0.71
Marktkapitalisierung:
$31.72B
Einnahmen:
$447.02M
Nettoeinkommen (Verlust:
$-1.18B
KGV:
-24.06
EPS:
-6.1812
Netto-Cashflow:
$-906.14M
1W Leistung:
-0.74%
1M Leistung:
-9.14%
6M Leistung:
+21.06%
1J Leistung:
+89.08%
1-Tages-Spanne:
$146.09
$152.19
1-Wochen-Bereich:
$142.99
$152.19
52-Wochen-Spanne:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
148.75 | 31.17B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-23 | Eingeleitet | Roth Capital | Buy |
| 2025-12-19 | Fortgesetzt | Truist | Buy |
| 2025-12-04 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-20 | Eingeleitet | William Blair | Outperform |
| 2025-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Eingeleitet | Jefferies | Buy |
| 2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
Will Insmed Incorporated outperform its industry peersProfit Target & Long-Term Safe Investment Plans - mfd.ru
Insmed To Present at March 2026 Investor Conferences - PR Newswire
Prospects for Insmed’s treprostinil palmitil as progressive pulmonary fibrosis treatment - The Pharma Letter
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz
Possible Bearish Signals With Insmed Insiders Disposing Stock - Yahoo Finance
Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 13,396 Shares of Stock - MarketBeat
Profund Advisors LLC Cuts Stock Holdings in Insmed, Inc. $INSM - MarketBeat
ING Groep NV Makes New $53.79 Million Investment in Insmed, Inc. $INSM - MarketBeat
Insmed, Inc. (NASDAQ:INSM) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Fund Update: 43,686 INSMED (INSM) shares added to CIBC Asset Management Inc portfolio - Quiver Quantitative
Essex Investment Management Co. LLC Grows Stake in Insmed, Inc. $INSM - MarketBeat
Insmed, Inc. $INSM Shares Sold by Envestnet Asset Management Inc. - MarketBeat
Candriam S.C.A. Has $57.26 Million Stock Position in Insmed, Inc. $INSM - MarketBeat
When Will Insmed Incorporated (NASDAQ:INSM) Become Profitable? - Yahoo Finance
Wellington Shields Capital Management LLC Invests $1.22 Million in Insmed, Inc. $INSM - MarketBeat
Insmed, Inc. $INSM Shares Sold by BI Asset Management Fondsmaeglerselskab A S - MarketBeat
Insider Sell: Martina Flammer Sells Shares of Insmed Inc (INSM) - GuruFocus
Valuation Update: Is Insmed Incorporated stock a buy or sell2025 Market Outlook & Verified High Yield Trade Plans - baoquankhu1.vn
Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026 - Financial Times
C WorldWide Group Holding A S Sells 75,000 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed (NASDAQ:INSM) Insider Michael Alexander Smith Sells 640 Shares - MarketBeat
Insider Selling: Insmed (NASDAQ:INSM) COO Sells 791 Shares of Stock - MarketBeat
William Lewis Sells 3,009 Shares of Insmed (NASDAQ:INSM) Stock - MarketBeat
Truist Financial Corp Sells 7,420 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed, Inc. $INSM Stock Holdings Lessened by WCM Investment Management LLC - MarketBeat
Insmed Presents Data on TPIP Inhalation Drug for PAH - respiratory-therapy.com
MACD Signal: What are the risks of holding Insmed Incorporated2025 Retail Activity & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Principal Financial Group Inc. Has $124.47 Million Holdings in Insmed, Inc. $INSM - MarketBeat
Keybank National Association OH Has $2.41 Million Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Mid-Cap Biopharmas Flex Their Commercial Muscle - Citeline News & Insights
Whale Trades: What are the risks of holding Insmed IncorporatedMarket Movement Recap & Capital Efficiency Focused Strategies - baoquankhu1.vn
Y Intercept Hong Kong Ltd Decreases Position in Insmed, Inc. $INSM - MarketBeat
Rate Cut: Will Insmed Incorporated outperform its industry peers2025 Trading Volume Trends & Low Drawdown Trading Techniques - baoquankhu1.vn
Bank of New York Mellon Corp Trims Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed (INSM) Sees Surge in Bullish Option Activity - GuruFocus
Morgan Stanley Updates Rating for Insmed (INSM), Adjusts Price T - GuruFocus
New York State Common Retirement Fund Buys 18,123 Shares of Insmed, Inc. $INSM - MarketBeat
What Insmed (INSM)'s Upcoming TPIP Data and New Analyst Coverage Mean For Shareholders - Yahoo Finance
Insmed TPIP Data At PVRI 2026 Tests Pulmonary Arterial Hypertension Ambitions - Yahoo Finance
Insmed (NASDAQ:INSM) Coverage Initiated at Barclays - MarketBeat
Definium Therapeutics Appoints Roger Adsett To Board - citybiz
Definium Therapeutics Appoints Roger Adsett to Board of Directors, Effective from January 29, 2025 - marketscreener.com
J. Safra Sarasin Holding AG Invests $1.09 Million in Insmed, Inc. $INSM - MarketBeat
Definium Therapeutics Appoints Roger Adsett to Board of Directors - Business Wire
Pulmonary Arterial Hypertension Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Ribomic, Gmax Biopharm, Novartis, Cereno Scientific AB, Insmed - Barchart.com
Barclays Initiates Coverage on Insmed With Overweight Rating, $231 Price Target - marketscreener.com
Barclays Initiates Coverage on Insmed (INSM) with Overweight Rat - GuruFocus
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress - PR Newswire
EFG Asset Management North America Corp. Reduces Stake in Insmed, Inc. $INSM - MarketBeat
Mutual of America Capital Management LLC Lowers Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Strs Ohio Grows Stake in Insmed, Inc. $INSM - MarketBeat
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.10%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):